People with Parkinson's design clinical trials charter to improve communication about, recruitment to and retention in Parkinson's clinical trials

Jon Stamford,Tom Isaacs,Camille Carroll

doi:10.1186/1745-6215-16-s2-p86

Abstract

Background A 2014 survey of people with Parkinson’s (PwPs) and clinicians internationally identified the following perceived barriers to clinical trial success in Parkinson’s disease (PD): fear of potential adverse consequences; communication failures and misunderstandings over the trial process (PwPs); and insufficient financial/administrative support (clinicians)[1]. In order to address these misperceptions, we have developed a clinical trials charter for use by those considering participating in, or conducting, Parkinson’s clinical research. The ultimate aim of the charter is to improve recruitment to and retention in clinical trials in PD.

Highlights

A 2014 survey of people with Parkinson’s (PwPs) and clinicians internationally identified the following perceived barriers to clinical trial success in Parkinson’s disease (PD): fear of potential adverse consequences; communication failures and misunderstandings over the trial process (PwPs); and insufficient financial/administrative support[1]
In order to address these misperceptions, we have developed a clinical trials charter for use by those considering participating in, or conducting, Parkinson’s clinical research
Submit your manuscript to BioMed Central and take full advantage of: Planned use The charter will be evaluated in an upcoming mullticentre randomised controlled trial of simvastatin as a neuroprotective agent in PD, by means of participant surveys, to understand its potential role in supporting recruitment and retention in Parkinson’s trials

Summary

Introduction

A 2014 survey of people with Parkinson’s (PwPs) and clinicians internationally identified the following perceived barriers to clinical trial success in Parkinson’s disease (PD): fear of potential adverse consequences; communication failures and misunderstandings over the trial process (PwPs); and insufficient financial/administrative support (clinicians)[1]. People with Parkinson’s design clinical trials charter to improve communication about, recruitment to and retention in Parkinson’s clinical trials From 3rd International Clinical Trials Methodology Conference Glasgow, UK.

Results

Conclusion